X | ||||||||||
- Definition Period which indicates the agreement expiration. No definition available.
|
X | ||||||||||
- Definition Future milestone payments to be made or received which are dependent on specific drug development milestones. No definition available.
|
X | ||||||||||
- Definition A description of the payment method of milestone expenses. No definition available.
|
X | ||||||||||
- Definition Expenses paid annual license fees paid during the period. No definition available.
|
X | ||||||||||
- Definition Payment made for the milestone expenses during the period. No definition available.
|
X | ||||||||||
- Definition Description relating to the sublicense fee payable on the percentage of net sales. No definition available.
|
X | ||||||||||
- Definition Percentage of revenue to be paid under the agreement on non-sales based revenue received. No definition available.
|
X | ||||||||||
- Definition Percentage of royalty revenue is derived from a stated amount of sales proceeds or revenue generated by the third party using the entity's property. No definition available.
|
X | ||||||||||
- Definition Payments made for maintenance of patents. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|